MARKET

ARDX

ARDX

Ardelyx
NASDAQ
6.75
-0.69
-9.27%
After Hours: 6.99 +0.24 +3.56% 19:58 05/24 EDT
OPEN
7.33
PREV CLOSE
7.44
HIGH
7.36
LOW
6.63
VOLUME
6.58M
TURNOVER
0
52 WEEK HIGH
10.13
52 WEEK LOW
3.160
MARKET CAP
1.58B
P/E (TTM)
-23.4131
1D
5D
1M
3M
1Y
5Y
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Wells Fargo released its annual biopharma M&A screen for 2024. The investment bank identified 31 companies in the SMid-cap space that demonstrate a high or medium fit to large-cap pharmaceutical companies. Viking, CRISPR, Intellia among potential acquisition targets for AbbVie and Gilead.
Seeking Alpha · 18h ago
Ardelyx slips as commercial chief departs
Healthcare Ardelyx slips as commercial chief departs May 24, 2024. Susan Rodriguez will continue to serve the company in an advisory role through the end of 2024. Rodriguez's resignation comes after the company announced the resignation of its chief commercial officer. Ar delyx, Inc. Shares trended lower on Friday.
Seeking Alpha · 1d ago
Ardelyx Is Maintained at Overweight by Piper Sandler
Dow Jones · 1d ago
Ardelyx Price Target Maintained With a $15.00/Share by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Maintains Overweight on Ardelyx, Maintains $15 Price Target
Benzinga · 1d ago
What Analysts Are Saying About Ardelyx Stock
Ardelyx Inc is a biotechnology company focused on the discovery, development and commercialization of new drugs. The company's revenue growth over the past three months has been noteworthy. ArdelyX has a 12-month price target of $. 5 analysts have published ratings on the company in the last three months.
Benzinga · 1d ago
Ardelyx Price Target Maintained With a $15.00/Share by Wedbush
Dow Jones · 1d ago
Wedbush Reiterates Outperform on Ardelyx, Maintains $15 Price Target
Benzinga · 1d ago
More
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Webull offers Ardelyx Inc stock information, including NASDAQ: ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.